Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management

  • Ahn, Yong Chan (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2019.06.03
  • Accepted : 2019.06.24
  • Published : 2019.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Concurrent chemoradiation therapy (CCRT) has played the most important and central role in the definitive therapy for the patients with locoregionally advanced stage nasopharynx cancer. The addition of induction chemotherapy (IC) or adjuvant chemotherapy (AC) to CCRT have been widely accepted with the rationale of improving distant control in the clinical practices. This review article investigated the role of IC and AC based on 11 recent meta-analysis publications, and found that the clinical benefits obtained by the additional IC or AC to CCRT, at the cost of the increased risks of more frequent and more severe side effects, seemed not big enough. More intervention is not always better, however, less seems frequently good enough. The author would speculate that 'less is more' and would advocate CCRT alone as the current standard.

Keywords

References

  1. Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015;16:645-55. https://doi.org/10.1016/S1470-2045(15)70126-9
  2. Song Y, Wang W, Tao G, Zhou X. Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma: a time-to-event meta-analysis. Oral Oncol 2015;51:764-9. https://doi.org/10.1016/j.oraloncology.2015.05.006
  3. Tan TH, Soon YY, Cheo T, et al. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: a systematic review and metaanalysis. Radiother Oncol 2018;129:10-7. https://doi.org/10.1016/j.radonc.2018.02.027
  4. Wang M, Tian H, Li G, et al. Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradi o therapy for l ocoregiona l ly advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials. Oncotarget 2016;7:48375-90. https://doi.org/10.18632/oncotarget.10237
  5. Chen YP, Guo R, Liu N, et al. Efficacy of the additional neoadjuvant chemotherapy to concurrent chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis of randomized controlled trials. J Cancer 2015;6:883-92. https://doi.org/10.7150/jca.11814
  6. Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res 2018;24:1824-33. https://doi.org/10.1158/1078-0432.CCR-17-2656
  7. Chen YP, Wang ZX, Chen L, et al. A Bayesian network metaanalysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2015;26:205-11. https://doi.org/10.1093/annonc/mdu507
  8. OuYang PY, Xie C, Mao YP, et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol 2013;24:2136-46. https://doi.org/10.1093/annonc/mdt146
  9. Yu H, Gu D, He X, Gao X, Bian X. The role of induction and adjuvant chemotherapy in combination with concurrent chemoradiotherapy for nasopharyngeal cancer: a Bayesian network meta-analysis of published randomized controlled trials. Onco Targets Ther 2016;9:159-70.
  10. Liu M, You W, Song YB, et al. The changing role of chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a updated systemic review and network metaanalysis. Front Oncol 2018;8:597. https://doi.org/10.3389/fonc.2018.00597
  11. Ribassin-Majed L, Marguet S, Lee AWM, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 2017;35:498-505. https://doi.org/10.1200/JCO.2016.67.4119
  12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: head and neck cancers (Version 1.2019) [Internet]. Plymouth Meeting, PA: National Comprehensive Cancer Network; c2019 [cited 2019 Jun 24]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
  13. Song JH, Wu HG, Keam BS, et al. The role of neoadjuvant chemotherapy in the treatment of nasopharyngeal carcinoma: a multi-institutional retrospective study (KROG 11-06) using propensity score matching analysis. Cancer Res Treat 2016;48:917-27. https://doi.org/10.4143/crt.2015.265
  14. Ahn YC, Kim YS. Korean perspectives of nasopharynx cancer management. Chin Clin Oncol 2016;5:28. https://doi.org/10.21037/cco.2016.03.01
  15. Lee H, Ahn YC, Oh D, Nam H, Noh JM, Park SY. Tumor volume reduction rate during adaptive radiation therapy as a prognosticator for nasopharyngeal cancer. Cancer Res Treat 2016;48:537-45. https://doi.org/10.4143/crt.2015.081
  16. Porter ME. What is value in health care? N Engl J Med 2010;363:2477-81. https://doi.org/10.1056/NEJMp1011024
  17. Rawlins MD. Cost, effectiveness, and value: how to judge? JAMA 2016;316:1447-8. https://doi.org/10.1001/jama.2016.11516

Cited by

  1. Dosimetric Comparison of Noncoplanar and Coplanar Volumetric Modulated Arc Therapy Plans for Esophageal Cancer vol.31, pp.4, 2019, https://doi.org/10.14316/pmp.2020.31.4.179
  2. An Updated Review on Head and Neck Cancer Treatment with Radiation Therapy vol.13, pp.19, 2019, https://doi.org/10.3390/cancers13194912